Supernus, Indivior agree all-stock merger, Indivior shareholders to get $1 billion special dividend
Reuters2026/08/03 10:35- Supernus agreed to merge with Indivior in an all-stock deal, creating a CNS-focused biopharma group with about USD 2.2 billion in annual revenue.
- Supernus holders will receive 1.5401 Indivior shares per Supernus share; Indivior holders will get a USD 1 billion special dividend pre-close.
- Dividend financing includes a USD 650 million term loan from Citibank N.A., with the balance funded from existing cash.
- Post-close ownership split set at about 56.5% for Indivior holders, 43.5% for Supernus holders; combined company to be named Supernus, ticker SUPN.
- Companies target USD 125 million in annual cost synergies; closing expected in Q4 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
OPEC+ agrees to keep oil output policy unchanged for October
US military strikes Iranian oil tanker, triggering geopolitical risks as Brent crude nears $97 mark
Following the US military's attack on Iranian oil tankers and Iran's announcement of new restricted navigation zones outside the Strait of Hormuz, market concerns over prolonged disruptions in key energy transport routes have intensified, leading to a sharp rise in international oil prices.
Geopolitical tensions overshadowing production cuts: OPEC+ maintains quotas unchanged, paper adjustments fail to resolve physical supply dilemmas
OPEC+ major oil producers, led by Saudi Arabia and Russia, held a monthly video conference last Sunday and decided to keep the crude oil production quota for October unchanged, continuing the previous tone of stable production following a series of symbolic production increases.
IX Biopharma seeks SGX-ST trading halt lift for shares in Singapore
Crypto prices
More
